429 related articles for article (PubMed ID: 34333087)
1. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).
Mercier C; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Debois H; Huget P; Verellen D
Radiat Oncol; 2018 Aug; 13(1):152. PubMed ID: 30126440
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
6. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
Olson R; Abraham H; Leclerc C; Benny A; Baker S; Matthews Q; Chng N; Bergman A; Mou B; Dunne EM; Schellenberg D; Jiang W; Chan E; Atrchian S; Lefresne S; Carolan H; Valev B; Tyldesley S; Bang A; Berrang T; Clark H; Hsu F; Louie AV; Warner A; Palma DA; Howell D; Barry A; Dawson L; Grendarova P; Walker D; Sinha R; Tsai J; Bahig H; Thibault I; Koul R; Senthi S; Phillips I; Grose D; Kelly P; Armstrong J; McDermott R; Johnstone C; Vasan S; Aherne N; Harrow S; Liu M
BMC Cancer; 2024 Feb; 24(1):171. PubMed ID: 38310262
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial.
Mercier C; Claessens M; Buys MSc A; Gryshkevych S; Billiet C; Joye I; Van Laere S; Vermeulen P; Meijnders P; Löfman F; Poortmans P; Dirix L; Verellen D; Dirix P
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1195-1205. PubMed ID: 33307151
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative body radiotherapy for lung cancer.
Franks KN; Jain P; Snee MP
Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
[TBL] [Abstract][Full Text] [Related]
9. CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.
Napieralska A; Miszczyk L; Stapor-Fudzinska M
Neoplasma; 2016; 63(2):304-12. PubMed ID: 26774153
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review.
Glicksman RM; Tjong MC; Neves-Junior WFP; Spratt DE; Chua KLM; Mansouri A; Chua MLK; Berlin A; Winter JD; Dahele M; Slotman BJ; Bilsky M; Shultz DB; Maldaun M; Szerlip N; Lo SS; Yamada Y; Vera-Badillo FE; Marta GN; Moraes FY
JAMA Oncol; 2020 Apr; 6(4):567-577. PubMed ID: 31895403
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
12. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.
David S; Tan J; Savas P; Bressel M; Kelly D; Foroudi F; Loi S; Siva S
Breast; 2020 Feb; 49():55-62. PubMed ID: 31734589
[TBL] [Abstract][Full Text] [Related]
15. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
16. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
[TBL] [Abstract][Full Text] [Related]
17. A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II).
Siva S; Kron T; Bressel M; Haas M; Mai T; Vinod S; Sasso G; Wong W; Le H; Eade T; Hardcastle N; Chesson B; Pham D; Høyer M; Montgomery R; Ball D
BMC Cancer; 2016 Mar; 16():183. PubMed ID: 26944262
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
19. Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive Patients.
Gandhidasan S; Ball D; Kron T; Bressel M; Shaw M; Chu J; Chander S; Wheeler G; Plumridge N; Chesson B; David S; Siva S
Clin Oncol (R Coll Radiol); 2018 Mar; 30(3):178-184. PubMed ID: 29224900
[TBL] [Abstract][Full Text] [Related]
20. Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.
Lehrer EJ; Singh R; Wang M; Chinchilli VM; Trifiletti DM; Ost P; Siva S; Meng MB; Tchelebi L; Zaorsky NG
JAMA Oncol; 2021 Jan; 7(1):92-106. PubMed ID: 33237270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
